FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists succeeded in eliminating the toxic properties of the glutamate-controlled NMDA-type neurotransmitter receptor.
FMP has already identified first drug candidates that are currently in pre-clinical development and will be tested in humans within the next 2-3 years.
The discovery of an entirely new pharmacological principle ('interface targeting') raises hopes that previously untreatable neurodegenerative diseases in humans can be mitigated. Interface inhibitors open up new possibilities, both in terms of drug treatments and gene therapy approaches.
FMP was established in 2016 as a biotech start-up of the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University by Professor Hilmar Bading, Junior Professor Daniela Mauceri and Dr. Thomas Schulze.
Spacing rules in the brain: Novel compounds that act as molecular spacers in the brain prevent neurodegeneration
Info & Contact
- Dr. Thomas Schulze, CEO
- +49 171 7860209
Dr. Thomas Schulze, CEO
c/o FundaMental Pharma GmbH
Johann-Fischer-Straße 2, 69121 Heidelberg